Filing Flows › Comparisons › OTLK vs INBX
Outlook Therapeutics vs Inhibrx Biosciences: OTLK and INBX compared
Outlook Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q3 FY25) against $1.3M for Inhibrx Biosciences (Q2 2025).
Where the money goes: OTLK and INBX
Outlook Therapeutics (OTLK) · Q3 FY25
Outlook Therapeutics, Q3 FY25: revenue $1.5M, net loss $20.2M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Inhibrx Biosciences (INBX) · Q2 2025
Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
| Outlook Therapeutics (OTLK) | Inhibrx Biosciences (INBX) | |
|---|---|---|
| Latest quarter | Q3 FY25 | Q2 2025 |
| Revenue | $1.5M | $1.3M |
| Revenue growth, Y/Y | — | 13× |
| Operating margin | n/m | n/m |
| Net earnings | −$20.2M | −$28.7M |
| Operating cash flow | −$11.9M | −$30.0M |
Questions
Which is bigger, Outlook Therapeutics or Inhibrx Biosciences?
Outlook Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q3 FY25) against $1.3M for Inhibrx Biosciences (Q2 2025).
More: Outlook Therapeutics earnings · how Outlook Therapeutics makes money · Inhibrx Biosciences earnings · how Inhibrx Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2025; 10-Q filed Aug 13, 2025). Fiscal quarters can end on different dates. Not investment advice.